Qelbree™ (viloxazine) – New drug approval
April 2, 2021 - Supernus Pharmaceuticals announced the FDA approval of Qelbree (viloxazine), for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age.
Download PDF
